These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31309507)

  • 21. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
    Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
    Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Protective effect of coli-proteus vaccine in an experimental animal model].
    Bĕlohlávek S; Konícková L
    Cesk Farm; 1980 May; 29(3-4):95-9. PubMed ID: 6996844
    [No Abstract]   [Full Text] [Related]  

  • 23. Independent Transurethral Urinary Tract Inoculation in a Murine Model of Ascending Infection with Proteus mirabilis.
    Smith SN
    Methods Mol Biol; 2019; 2021():159-172. PubMed ID: 31309504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of green fluorescent protein to assess urease gene expression by uropathogenic Proteus mirabilis during experimental ascending urinary tract infection.
    Zhao H; Thompson RB; Lockatell V; Johnson DE; Mobley HL
    Infect Immun; 1998 Jan; 66(1):330-5. PubMed ID: 9423875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral vaccination against Porteus mirabilis.
    Jones RJ
    Br J Exp Pathol; 1976 Aug; 57(4):395-9. PubMed ID: 822863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of novel putative immunogenic targets against Proteus mirabilis using a reverse vaccinology approach.
    Noori Goodarzi N; Bolourchi N; Fereshteh S; Badmasti F
    Infect Genet Evol; 2021 Nov; 95():105045. PubMed ID: 34428568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allicin prevents the formation of Proteus-induced urinary crystals and the blockage of catheter in a bladder model in vitro.
    Imani Rad H; Peeri H; Amani M; Mohammadnia A; Ogunniyi AD; Khazandi M; Venter H; Arzanlou M
    Microb Pathog; 2019 Jul; 132():293-301. PubMed ID: 31082531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model.
    Fraga M; Scavone P; Zunino P
    Antonie Van Leeuwenhoek; 2005 Jul; 88(1):25-34. PubMed ID: 15928974
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Fitzgerald MJ; Pearson MM; Mobley HLT
    J Bacteriol; 2024 Apr; 206(4):e0003124. PubMed ID: 38534115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model.
    Moayeri N; Collins CM; O'Hanley P
    Infect Immun; 1991 Oct; 59(10):3778-86. PubMed ID: 1894376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UreR, the transcriptional activator of the Proteus mirabilis urease gene cluster, is required for urease activity and virulence in experimental urinary tract infections.
    Dattelbaum JD; Lockatell CV; Johnson DE; Mobley HL
    Infect Immun; 2003 Feb; 71(2):1026-30. PubMed ID: 12540589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold.
    Burall LS; Harro JM; Li X; Lockatell CV; Himpsl SD; Hebel JR; Johnson DE; Mobley HL
    Infect Immun; 2004 May; 72(5):2922-38. PubMed ID: 15102805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection.
    Pearson MM; Mobley HLT
    J Med Microbiol; 2007 Oct; 56(Pt 10):1277-1283. PubMed ID: 17893161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of Proteus mirabilis in Catheter-Associated Urinary Tract Infections.
    Yuan F; Huang Z; Yang T; Wang G; Li P; Yang B; Li J
    Urol Int; 2021; 105(5-6):354-361. PubMed ID: 33691318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Pathogenic Potential of Proteus mirabilis Is Enhanced by Other Uropathogens during Polymicrobial Urinary Tract Infection.
    Armbruster CE; Smith SN; Johnson AO; DeOrnellas V; Eaton KA; Yep A; Mody L; Wu W; Mobley HLT
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.
    Nielubowicz GR; Smith SN; Mobley HL
    Infect Immun; 2008 Sep; 76(9):4222-31. PubMed ID: 18625734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of inhibitory activity of domestic probiotics for against invasion and infection by Proteus mirabilis in the urinary tract.
    Lai TM; Lin PP; Hsieh YM; Tsai CC
    J Infect Dev Ctries; 2020 Apr; 14(4):366-372. PubMed ID: 32379713
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Manoharan A; Farrell J; Aldilla VR; Whiteley G; Kriel E; Glasbey T; Kumar N; Moore KH; Manos J; Das T
    Front Cell Infect Microbiol; 2023; 13():1216798. PubMed ID: 37965267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of effectiveness and safety of Ibicella lutea extract in the control of experimental Proteus mirabilis urinary tract infection.
    Sosa V; Zunino P
    J Infect Dev Ctries; 2010 Dec; 4(12):814-21. PubMed ID: 21252462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Protective properties of antigenic complexes of Proteus].
    Kreĭnin LS; Kaverina KG; Aksenova EV; Buatkova LIu
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Jan; (1):60-4. PubMed ID: 7015763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.